Compare Amylx Pharmaceuticals Inc (AMLX) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Linde PLC — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Linde PLC trades at $531.24 (market cap $244.95B). The key difference: Linde PLC is far larger — about 123.7× Amylx Pharmaceuticals Inc's market cap, and Linde PLC pays a 1.21% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | LIN | |
|---|---|---|
Market Cap | $1.98B | $244.95B |
Sector | Health | Basic Materials |
52-Week High | $18.70 | $546.64 |
52-Week Low | $7.64 | $389.38 |
Enterprise Value | $1.70B | $267.30B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Linde PLC (LIN) trades at $529.79, up 0.8% today, with strong analyst support (24 buy, 4 hold) and a consensus price target of $560. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.33 exceeding estimates, and robust fundamentals including a 20.44% net margin and 18.49% ROE. Technical indicators are bullish overall, with the current price near resistance at $529.
Outlook remains positive due to steady revenue growth, high profitability, and shareholder returns via dividends. Risks include elevated valuation multiples (P/E 35.13) and rising debt-to-asset ratio. The stock offers a balanced opportunity for growth investors, supported by strong institutional sentiment and operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
